You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

Details for Patent: 10,918,622


✉ Email this page to a colleague

« Back to Dashboard



Drugs Protected by US Patent 10,918,622

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Loxo Oncol JAYPIRCA pirtobrutinib TABLET;ORAL 216059-001 Jan 27, 2023 RX Yes No 10,918,622 ⤷  Subscribe TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR ⤷  Subscribe
Loxo Oncol JAYPIRCA pirtobrutinib TABLET;ORAL 216059-001 Jan 27, 2023 RX Yes No 10,918,622 ⤷  Subscribe ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR ⤷  Subscribe
Loxo Oncol JAYPIRCA pirtobrutinib TABLET;ORAL 216059-002 Jan 27, 2023 RX Yes Yes 10,918,622 ⤷  Subscribe TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR ⤷  Subscribe
Loxo Oncol JAYPIRCA pirtobrutinib TABLET;ORAL 216059-002 Jan 27, 2023 RX Yes Yes 10,918,622 ⤷  Subscribe ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,918,622

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3390395 ⤷  Subscribe CA 2024 00006 Denmark ⤷  Subscribe
European Patent Office 3390395 ⤷  Subscribe 301262 Netherlands ⤷  Subscribe
European Patent Office 3390395 ⤷  Subscribe LUC00330 Luxembourg ⤷  Subscribe
European Patent Office 3390395 ⤷  Subscribe PA2024506 Lithuania ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.